Tag: Talazoparib

The list price of a 30-day supply of Talzenna (talazoparib) can exceed $18,000 without insurance, making cost a significant concern for many patients. Navigating the expenses associated with this powerful PARP inhibitor, which is used to treat certain types of breast and prostate cancer, requires understanding the complex factors influencing its price. Fortunately, options like insurance coverage, manufacturer co-pay cards, and patient assistance programs can help offset the high cost of Talzenna.

As part of an effort to enhance manufacturing efficiency, Pfizer has introduced a new soft gelatin capsule formulation for Talzenna (talazoparib). This modification maintains the medication's therapeutic properties. This raises the question: What is the new formulation of Talzenna, and how does this update impact individuals currently using the drug?

The FDA approved talazoparib, the generic name for Talzenna, for certain types of advanced breast cancer in 2018. Talzenna is a targeted therapy known as a PARP inhibitor, which is prescribed for specific cancers with particular genetic mutations. This article explains what is the generic name for Talzenna, its mechanism of action, and how it is used in cancer treatment.

The cost of specialty oncology drugs is notoriously high, and Talzenna (talazoparib) is no exception. For those without comprehensive insurance, finding out **how much is Talzenna 1mg in the US** can reveal a significant financial burden, but numerous financial assistance options are available to help manage these expenses.